Zhongxin Jingwei, December 29 According to the news of the Shandong Securities Regulatory Bureau on the 29th, the Shandong Securities Regulatory Bureau issued a warning letter to Ruikang Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Ruikang Pharmaceutical") and related personnel.
*: Shandong Securities Regulatory Bureau**.
The Shandong Securities Regulatory Bureau said that after investigation, Ruikang Pharmaceutical had the following problems.
First, it failed to disclose related party transactions, financial assistance and other matters as required. In October 2021, Ruikang Pharmaceutical subscribed and increased its capital by 460 million yuan to Shandong Lekang Jinyue Industry *** hereinafter referred to as Lekang Jinyue, which is an enterprise jointly invested by Ruikang Pharmaceutical and Yantai Chenghou Investment, a related party of the controlling shareholder, and the capital increase constitutes a related party transaction. At the same time, Ruikang Pharmaceutical and Yantai Chenghou have provided financial assistance to Lekang Jinyue many times, and there have been capital exchanges. For the above matters, Ruikang Pharmaceutical failed to perform the corresponding review procedures and information disclosure obligations in accordance with the regulations. The above-mentioned behavior of Ruikang Pharmaceutical violated Articles 3 and 41 of the Administrative Measures for Information Disclosure of Listed Companies (Decree No. 182 of the CSRC).
Second, failure to timely disclose major litigation and arbitration matters as required. As of May 8, 2023, the cumulative amount of litigation and arbitration matters in Ruikang Pharmaceutical has reached 58,360 in 12 consecutive months960,000 yuan, touching the interim report disclosure standards for major litigation and arbitration matters, and the cumulative amount and proportion involved in the litigation and arbitration of Ruikang Pharmaceutical for 12 consecutive months have also touched the interim report disclosure standards many times, and the company has not fulfilled the interim report disclosure obligations in a timely manner. It was not until August 30, 2023 that Ruikang Pharmaceutical disclosed the "Announcement on the Cumulative Litigation". The above-mentioned behavior of Ruikang Pharmaceutical violated Articles 3, 22 and 26 of the Administrative Measures for Information Disclosure of Listed Companies (Decree No. 182 of the CSRC).
According to Articles 4 and 51 of the Administrative Measures for Information Disclosure of Listed Companies (Decree No. 182 of the CSRC), Han Xu, as the then chairman, Zhang Renhua, as the then general manager, Feng Yun, as the then chief financial officer, and Zhou Yun, as the then secretary of the board of directors, were primarily responsible for the first act mentioned aboveHan Xu, as the then chairman and president, Zhang Renhua as the then general manager, Zhou Yun as the then secretary of the board of directors, and Li Zhe as the then director acting as the secretary of the board of directors, are primarily responsible for the above second act. According to the relevant regulations, the Shandong Securities Regulatory Bureau decided to take administrative supervision measures to issue warning letters to Ruikang Pharmaceutical and Han Xu, Zhang Renhua, Feng Yun, Zhou Yun and Li Zhe, and recorded the relevant situation in the market integrity file database.
According to public information, Ruikang Pharmaceutical's main business is drug sales. In the first three quarters of 2023, Ruikang Pharmaceutical achieved revenue of 610.5 billion yuan, a year-on-year decrease of 4397%；net profit attributable to shareholders of listed companies was 19.22 million yuan, down 6854%。
Ruikang Pharmaceutical closed up 062% to 327 yuan shares, down 20 during the year63%, with a total market value of 4.9 billion yuan. (Zhongxin Jingwei app).
For more exciting content, please pay attention to the official WeChat of JWVIEW***